Product Name: 5-Bromo-2-chlorobenzoic Acid
CAS No.: 21739-92-4
🔬 Product Overview
A high-purity pharmaceutical intermediate widely used in synthesizing SGLT2 inhibitors such as Dapagliflozin and Empagliflozin, key drugs for treating type 2 diabetes, heart failure, and chronic kidney disease13. With a purity of ≥98% (HPLC), it ensures reliable quality for API production. Available in bulk quantities (1kg to 25kg) and compliant with global pharmaceutical standards12.
📊 Key Advantages
✅ High Purity: ≥98% (HPLC/GC-certified), ideal for API synthesis14.
📦 Flexible Packaging: Customizable formats (1kg, 5kg, 25kg) for industrial and lab use24.
💊 Critical Role: Key building block for SGLT2 inhibitors with a global market projected to grow at 10.3% CAGR (2025–2030)35.
💊 Applications
Pharmaceutical Synthesis: Core intermediate for Dapagliflozin (CAS 461432-26-8) and Empagliflozin production13.
R&D: Supports development of novel antidiabetic and cardiovascular therapies35.
Export & Reagents: Widely used in scientific research and chemical reagent markets46.
📜 Quality Certification
Testing Standards: HPLC, GC, NMR, and mass spectrometry12.
Compliance: Meets ISO 9001 and ICH Q7 guidelines for pharmaceutical intermediates14.
🌍 Market Trends
The demand for 5-Bromo-2-chlorobenzoic Acid is surging due to rising diabetes prevalence and expanded indications for SGLT2 inhibitors. Dapagliflozin alone holds approvals for 3 major therapeutic areas, driving API production growth35. Asia-Pacific has emerged as a key manufacturing hub, with suppliers offering GMP-compliant batches gaining strategic partnerships13.
China
